Prednisone
Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
26 Active assets in the Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dexasone Princess Maxima Center for Pediatric Oncology | Phase 1/2 | CCC |
Prednisolone Children's Oncology Group | Phase 1/2 | CCC |
Rituximab M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Fludarabine Children's Oncology Group | Phase 1/2 | CCC |
Methotrexate Children's Oncology Group | Phase 1/2 | CCC |
View all 34 →
Same molecule, other indications
Prednisone is also rated in:
peripheral T-cell lymphoma, not otherwise specifiedActive
BBB
Indicative · Phase 4
74 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →